New hope for Hard-to-Treat breast cancer: drug combo targets gene mutation
Disease control
Recruiting now
This study tests whether a new drug combination (lasofoxifene plus abemaciclib) works better than a standard combination (fulvestrant plus abemaciclib) for people with advanced ER+/HER2- breast cancer that has a specific gene change (ESR1 mutation). About 500 adults whose cancer …
Phase: PHASE3 • Sponsor: LeonaBio • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC